+38 044 223 28 95
00380930552240 (باللغة العربية)
+38 044 223 28 95
Request Info

News and articles on heart diseases

Clinical Trial Shows Efficacy of Stem Cell Medicine for Heart Failure Patients 25 July 2015

A Stem cell based medicine Heartcel shows promising results in patients suffering from advanced heart failure.

Embryonic Stem Cells Will Be Tested for Heart Failure and Type 1 Diabetes 19 October 2014

Human embryonic stem cells will be tested in clinical trials as a treatment for two major devastating diseases: heart failure and type 1 diabetes.

Fetal stem cells prove effective in combined treatment of chronic heart failure 10 September 2014

Combined treatment of heart failure patients with fetal stem cells showed significant improvements in the contractile function of the left ventricle myocardium, as well as in patients’ cognitive and emotional states.

The largest to date trial of adult stem cells in heart attack patients begins 24 February 2014

A total of 3,000 patients will be involved in the trial to test whether life can be prolonged by administering stem cells from the patient's own bone marrow.

All news

Heart Treatment

Transplantation of fetal stem cell suspensions in rehabilitation period in postinfarction cardiosclerosis and hypertension patients has positive effects on overall health as well as on rheological (flow) properties of blood. These effects have been proved by clinical data of postinfarction and other ischemic heart disease patients followed up at Cell Therapy Center EmCell.

When using fetal cell suspensions containing stem cells, syndrome of early posttransplantation improvements is observed in all patients. The major manifestations of this syndrome include decreased weakness, improved overall health and appetite, normalized sleep formula, positive changes in psychoemotional sphere, such as reduced manifestation of somatic depression, improved emotional state, thinking, memory and hope for recovery. 80% of patients report gradual decrease of blood pressure, at first, taking the pretransplantation dose of antihypertensive drugs, but 2-4 weeks after the stem cell transplantation, 45-50% of patients reduce the dose of nitrates and antihypertensive drugs. Also, in all cases observed is gradual decrease and normalization of cholesterol, triglycerides, as well as low and very low density lipoproteins levels. Almost all our patients improve rheological properties of blood that can be related to the increase in prothrombin index and prolongation of coagulation time.

Due to formation of the alternative (additional) systems of collateral vessels in the cardiac muscle, tissue trophism significantly improves, manifestations of ischemia become less expressed, frequency and intensity of angina attacks decrease, and metabolism in myocardium improves.

Improvement in overall health and better ability to work motivate patients to extend their physical activities and return to their working career. All this taken as a whole improves life quality of ischemic heart disease patients and significantly (by 35%) extends their life span.

Fetal Stem Cells in Combination Treatment of Chronic Heart Failure. Poster session.


Patient K.F., 65. IHD: diffuse cardiosclerosis. Atherosclerosis of aorta and coronary arteries with stenosis. Grade I heart failure with preserved LV systolic function, NYHA Class I

Patient A.M., 49. Dilated cardiomyopathy

Patient H.B., 56. IHD: Stable effort angina, NYHA II. Diffuse and postinfarction cardiosclerosis. Atherosclerosis of aorta and coronary arteries with stenosis. S.p. transluminal angioplasty with 4 stents placement.   Subtotal stenosis of the posterior descending artery (branch of the right coronary artery). Essential  hypertension. Moderate decompensated type 2 diabetes mellitus. Hyperuricemia.

Request additional information

Our stories